Shanghai 6th People's Hospital — Biomedical Watch V2

Traitements3programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Multi-mode tumor treatment systemThe goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its application value by comparing preoperative and postoperative immune indicators.	Cancer	Phase 2		China	À vérifier
Sintilimab+mFOLFOX6 or FOLFIRI+bevacizumab or cetuximabThe goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its application value by comparing preoperative and postoperative immune indicators.	Cancer	Phase 2		China	À vérifier
Multi-mode tumor treatment systemThe goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its application value by comparing preoperative and postoperative immune indicators.	Cancer	Phase 2		China	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Multi-mode tumor treatment system	Cancer	Phase 2	NCT06590259	A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.